Roles of UBE2C in breast cancer and its clinical significance

doi:10.3760/cma.j.issn.1673-422X.2015.10.013

Abstract

Abstract: Ubiquitinconjugating enzyme 2C (UBE2C) is involved in cell cycle progression, mitosis regulation and targeted degradation of shortlived proteins. UBE2C is the cancerrelated ubiquitinconjugating enzyme, which is significantly higher in breast cancer tissues compared to the adjacent normal tissue. The abnormal expression of UBE2C participates in the process of occurrence, development and metastasis of breast cancer by the regulation of cell cycle progression, CerbB2, cell apoptosis factors and metastasis related genes. It will provide reference for the diagnosis and prognosis of breast cancer.

Key words: Cell cycle, Breast neoplasms, Ubiquitinconjugating enzyme 2C

Qin Tao, Li Man.. Roles of UBE2C in breast cancer and its clinical significance[J]. Journal of International Oncology, 2015, 42(10): 766-768.

References

［1］ Zhou MJ, Chen FZ, Chen HC. Ubiquitination involved enzymes and cancer［J］. Med Oncol, 2014, 31(8): 93. ［2］ Lin Y, Hwang WC, Basavappa R. Structural and functional analysis of the human mitoticspecific ubiquitinconjugating enzyme UbcH10［J］. J Biol Chem, 2002, 277(24): 21913-21921. ［3］ Nath S, Banerjee T, Sen D, et al. Spindle assembly checkpoint protein Cdc20 transcriptionally activates expression of ubiquitin carrier protein UbcH10［J］. J Biol Chem, 2011, 286(18): 15666-15677. ［4］ Meyer HJ, Rape M. Processive ubiquitin chain formation by the anaphasepromoting complex［J］. Semin Cell Dev Biol, 2011, 22(6): 544-550. ［5］ Rape M, Reddy SK, Kirschner MW. The processivity of multiubiquitination by the APC determines the order of substrate degradation［J］. Cell, 2006, 124(1): 89-103. ［6］ Hao Z, Zhang H, Cowell J. Ubiquitinconjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker［J］. Tumour Biol, 2012, 33(3): 723-730. ［7］ Berlingieri MT, Pallante P, Sboner A, et al. UbcH10 is overexpressed in malignant breast carcinomas［J］. Eur J Cancer, 2007, 43(18): 2729-2735. ［8］ Rawat A, Gopal G, Selvaluxmy G, et al. Inhibition of ubiquitin conjugating enzyme UBE2C reducesproliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole［J］. Cell Oncol, 2013, 36(6): 459-467. ［9］ Endesfelder D, Burrell R, Kanu N, et al. Chromosomal instability selects gene copy number variants encoding core regulators of proliferation in ER+ breast cancer［J］. Cancer Res, 2014, 74(17): 4853-4863. ［10］ Fujita T, Ikeda H, Kawasaki K, et al. Clinicopathological relevance of UbcH10 in breast cancer［J］. Cancer Sci, 2009, 100(2): 238-248. ［11］ Lu J, Wen M, Huang Y, et al. C2ORF40 suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes［J］. Epigenetics, 2013, 8(6): 571-583. ［12］ Wang S, Rijk JC, Pen MJ, et al. A lowdensity DNA microchip for the detection of (anti)estrogenic compounds and their relative potencies［J］. Analytical Biochemistry, 2013, 435(1): 83-92. ［13］ Lai HW, Chien SY, Kuo SJ, et al. The potential utility of curcumin in the treatment of HER2overexpressed breast cancer: an in vitro and in vivo comparison study with herceptin［J］. Evid Based Complement Alternat Med, 2012, 2012: 486568. ［14］王银平, 殷志强, 陈雪华. UbcH10在乳腺癌中的表达及意义［J］. 外科理论与实践, 2008, 13(2): 149-152. ［15］ Jancík S, Drábek J, Radzioch D, et al. Clinical relevance of KRAS in human cancers［J］. J Biomed Biotechnol, 2010, 2010: 150960. ［16］ Chou CP, Huang NC, Jhuang SJ, et al. Ubiquitinconjugating enzyme UBE2C is highly expressed in breast microcalcification lesions［J］. PLoS One, 2014, 9(4): e93934. ［17］ Loussouarn D, Campion L, Leclair F, et al. Validation of UBE2C protein as a prognostic marker in nodepositive breastcancer［J］. Br J Cancer, 2009, 101(1): 166-173. ［18］ Taylor KJ, Sims AH, Liang L, et al. Dynamic changes in gene expression in vivo predict prognosis of tamoxifentreated patients with breast cancer［J］. Breast Cancer Res, 2010, 12(3): R39.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[10]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[13]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.
[14]	Li Lixi, Zhang Di, Luo Yang, Ma Fei. Clinical application of PARP inhibitors in breast cancer [J]. Journal of International Oncology, 2023, 50(2): 91-96.
[15]	Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng. Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors [J]. Journal of International Oncology, 2023, 50(11): 650-654.